KR20240090898A - 암을 치료 및 예방하고 btk를 분해하기 위한 피페리디닐피라진-카복스아미드 화합물 - Google Patents

암을 치료 및 예방하고 btk를 분해하기 위한 피페리디닐피라진-카복스아미드 화합물 Download PDF

Info

Publication number
KR20240090898A
KR20240090898A KR1020247017265A KR20247017265A KR20240090898A KR 20240090898 A KR20240090898 A KR 20240090898A KR 1020247017265 A KR1020247017265 A KR 1020247017265A KR 20247017265 A KR20247017265 A KR 20247017265A KR 20240090898 A KR20240090898 A KR 20240090898A
Authority
KR
South Korea
Prior art keywords
compound
cancer
formula
certain embodiments
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247017265A
Other languages
English (en)
Korean (ko)
Inventor
로버트 제이. 브라운
아서 티. 샌즈
Original Assignee
누릭스 테라퓨틱스 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 누릭스 테라퓨틱스 인코포레이티드 filed Critical 누릭스 테라퓨틱스 인코포레이티드
Publication of KR20240090898A publication Critical patent/KR20240090898A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020247017265A 2021-10-26 2022-10-25 암을 치료 및 예방하고 btk를 분해하기 위한 피페리디닐피라진-카복스아미드 화합물 Pending KR20240090898A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163263081P 2021-10-26 2021-10-26
US63/263,081 2021-10-26
US202263391671P 2022-07-22 2022-07-22
US63/391,671 2022-07-22
PCT/US2022/047767 WO2023076303A1 (en) 2021-10-26 2022-10-25 Piperidinylpyrazine-carboxamide compounds for treating and preventing cancer and for degrading btk

Publications (1)

Publication Number Publication Date
KR20240090898A true KR20240090898A (ko) 2024-06-21

Family

ID=84361163

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247017265A Pending KR20240090898A (ko) 2021-10-26 2022-10-25 암을 치료 및 예방하고 btk를 분해하기 위한 피페리디닐피라진-카복스아미드 화합물

Country Status (9)

Country Link
US (1) US12377106B2 (https=)
EP (1) EP4422630A1 (https=)
JP (1) JP2024542984A (https=)
KR (1) KR20240090898A (https=)
AU (1) AU2022379494A1 (https=)
CA (1) CA3236073A1 (https=)
IL (1) IL312357A (https=)
MX (1) MX2024004899A (https=)
WO (1) WO2023076303A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021004191A (es) 2018-10-15 2021-05-27 Nurix Therapeutics Inc Compuestos bifuncionales para degradar la tirosina cinasa de bruton (btk) mediante la trayectoria de ubiquitina proteosoma.
US12582722B2 (en) 2019-02-13 2026-03-24 Nurix Therapeutics, Inc. Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway
WO2021113557A1 (en) 2019-12-04 2021-06-10 Nurix Therapeutics, Inc. Bifunctional compounds for degrading btk via ubiquitin proteosome pathway
CA3236073A1 (en) 2021-10-26 2023-05-04 Robert J. Brown Piperidinylpyrazine-carboxamide compounds for treating and preventing cancer and for degrading btk

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070054355A1 (en) 2003-03-05 2007-03-08 Yuval Reiss Cbl-b polypeptides, complexes and related methods
WO2007072225A2 (en) 2005-12-01 2007-06-28 Medical Prognosis Institute Methods and devices for identifying biomarkers of treatment response and use thereof to predict treatment efficacy
WO2008033403A2 (en) 2006-09-13 2008-03-20 The Trustees Of Columbia University In The City Of New York Agents and methods to elicit anti-tumor immune response
AT506041A1 (de) 2007-12-10 2009-05-15 Univ Innsbruck Verfahren zur erhöhung der immunreaktivität
PL2242749T3 (pl) 2008-02-05 2013-09-30 Hoffmann La Roche Nowe pirydynony i pirydazynony
EP2440204B1 (en) 2009-06-12 2013-12-18 Bristol-Myers Squibb Company Nicotinamide compounds useful as kinase modulators
EP2566869B1 (en) 2010-05-07 2016-03-02 Gilead Connecticut, Inc. Pyridone and aza-pyridone compounds and methods of use
AR082590A1 (es) 2010-08-12 2012-12-19 Hoffmann La Roche Inhibidores de la tirosina-quinasa de bruton
EP2471548A1 (de) 2010-12-28 2012-07-04 Apeiron Biologics AG siRNA gegen Cbl-b und optional IL2 und IL12 zur Verwendung in der Behandlung von Krebs
UA111756C2 (uk) 2011-11-03 2016-06-10 Ф. Хоффманн-Ля Рош Аг Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона
MX2014005282A (es) 2011-11-03 2014-05-30 Hoffmann La Roche Compuestos de 8-fluoroftalazin-1 (2h) -ona.
KR102668696B1 (ko) 2012-01-12 2024-05-29 예일 유니버시티 E3 유비퀴틴 리가아제에 의한 표적 단백질 및 다른 폴리펩티드의 증진된 분해를 위한 화합물 및 방법
WO2014040965A1 (en) 2012-09-13 2014-03-20 F. Hoffmann-La Roche Ag Inhibitors of bruton's tyrosine kinase
US10308707B2 (en) 2013-12-02 2019-06-04 Aaron Diamond Aids Research Center Bispecific HIV-1-neutralizing antibodies
US9382246B2 (en) 2013-12-05 2016-07-05 Pharmacyclics Llc Inhibitors of Bruton's tyrosine kinase
GB201506871D0 (en) 2015-04-22 2015-06-03 Glaxosmithkline Ip Dev Ltd Novel compounds
MX2017015574A (es) 2015-06-02 2018-08-09 Pharmacyclics Llc Inhibidores de tirosina quinasa de bruton.
AU2016297362B2 (en) 2015-07-17 2020-04-16 Takeda Pharmaceutical Company Limited Oxadiazole derivatives useful as HDAC inhibitors
HUE066460T2 (hu) 2016-10-26 2024-08-28 Iovance Biotherapeutics Inc A kriokonzervált tumor infiltráló limfociták restimulációja
TWI788307B (zh) 2016-10-31 2023-01-01 美商艾歐凡斯生物治療公司 用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
CA3042297A1 (en) 2016-11-22 2018-05-31 Dana-Farber Cancer Institute, Inc. Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and methods of use
WO2018106870A1 (en) 2016-12-08 2018-06-14 Icahn School Of Medicine At Mount Sinai Compositions and methods for treating cdk4/6-mediated cancer
JOP20190224A1 (ar) 2017-03-29 2019-09-26 Iovance Biotherapeutics Inc عمليات من أجل إنتاج الخلايا اللمفاوية المرتشحة للأورام واستخداماتها في العلاج المناعي
EP3743063A4 (en) 2018-01-26 2021-10-20 Nurix Therapeutics, Inc. CBL-B INHIBITORS AND THEIR METHODS OF USE
EP3746426A4 (en) 2018-01-29 2021-12-29 Dana Farber Cancer Institute, Inc. Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and methods of use
CN112584852A (zh) * 2018-06-19 2021-03-30 百欧恩泰美国公司 新抗原及其用途
MX2021004191A (es) 2018-10-15 2021-05-27 Nurix Therapeutics Inc Compuestos bifuncionales para degradar la tirosina cinasa de bruton (btk) mediante la trayectoria de ubiquitina proteosoma.
US12582722B2 (en) 2019-02-13 2026-03-24 Nurix Therapeutics, Inc. Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway
CA3136348A1 (en) 2019-04-09 2020-10-15 Nurix Therapeutics, Inc. 3-substituted piperidine compounds for cbl-b inhibition, and use of a cbl-b inhibitor in combination with a cancer vaccine and/or oncolytic virus
AU2020278592B2 (en) 2019-05-17 2024-10-10 Nurix Therapeutics, Inc. Cyano cyclobutyl compounds for Cbl-b inhibition and uses thereof
MX2021015675A (es) 2019-06-26 2022-02-03 Nurix Therapeutics Inc Compuestos de bencil-triazol sustituidos para la inhibicion de cbl-b y otros usos de los mismos.
AU2020320195A1 (en) 2019-07-30 2022-03-10 Nurix Therapeutics, Inc. Urea, amide, and substituted heteroaryl compounds for Cbl-b inhibition
EP4034140A1 (en) 2019-09-24 2022-08-03 Nurix Therapeutics, Inc. Cbl inhibitors and compositions for use in adoptive cell therapy
US20230024442A1 (en) 2019-11-08 2023-01-26 Nurix Therapeutics, Inc. Bifunctional compounds for grading btk via ubiquitin proteosome pathway
WO2021113557A1 (en) * 2019-12-04 2021-06-10 Nurix Therapeutics, Inc. Bifunctional compounds for degrading btk via ubiquitin proteosome pathway
AU2022310182A1 (en) 2021-07-14 2024-02-01 Nurix Therapeutics, Inc. Bifunctional compounds for degrading btk with diminished imid activity
CN118019539A (zh) 2021-07-23 2024-05-10 纽力克斯治疗公司 用于降解BTK并具有增强的IMiD活性的双官能化合物
CA3236073A1 (en) 2021-10-26 2023-05-04 Robert J. Brown Piperidinylpyrazine-carboxamide compounds for treating and preventing cancer and for degrading btk

Also Published As

Publication number Publication date
EP4422630A1 (en) 2024-09-04
US12377106B2 (en) 2025-08-05
AU2022379494A1 (en) 2024-05-30
US20230149416A1 (en) 2023-05-18
CA3236073A1 (en) 2023-05-04
IL312357A (en) 2024-06-01
JP2024542984A (ja) 2024-11-19
MX2024004899A (es) 2024-05-24
WO2023076303A1 (en) 2023-05-04

Similar Documents

Publication Publication Date Title
JP7741282B2 (ja) ユビキチンプロテオソーム経路を介してｂｔｋを分解するための二官能性化合物
US12600732B2 (en) Bifunctional compounds for degrading BTK via ubiquitin proteosome pathway
US12377106B2 (en) Piperidinylpyrazine-carboxamide compounds for treating and preventing cancer and for degrading BTK
US11053197B2 (en) Carbazole derivatives
CN103764653B (zh) 作为c-Kit激酶抑制剂的化合物和组合物
EP2763975B1 (en) 3-pyridyl carboxamide-containing spleen tyrosine kinase (syk) inhibitors
EP4334302A1 (en) Compounds for inhibiting or degrading target proteins, compositions, comprising the same, methods of their making, and methods of their use
CN107849017A (zh) 作为magl抑制剂的1,1,1‑三氟‑3‑羟基丙‑2‑基氨基甲酸酯衍生物及1,1,1‑三氟‑4‑羟基丁‑2‑基氨基甲酸酯衍生物
JP7825640B2 (ja) Ｉｔｋを阻害又は分解するための化合物、それを含む組成物、それらの作製方法及びそれらの使用方法
JP2019518059A (ja) ＰＩ３Ｋβ阻害剤としてのアザベンゾイミダゾール誘導体
US20180230152A1 (en) Compounds inhibiting leucine-rich repeat kinase enzyme activity
KR20190092549A (ko) Cdk4/6 억제제
WO2020030925A1 (en) Heterocyclic substituted ureas, for use against cancer
AU2017324281A1 (en) 8-(azetidin-1-yl)-[1,2,4]triazolo[1,5-A]pyridinyl compounds, compositions and methods of use thereof
CN118475352A (zh) 用于治疗和预防癌症以及用于降解btk的哌啶基吡嗪-甲酰胺类化合物
RU2852021C2 (ru) Новые ингибиторы JAK1-киназ
HK40081936A (en) Bifunctional compounds for degrading btk via ubiquitin proteosome pathway
JP2025532179A (ja) サイクリン依存性キナーゼ７阻害剤
BR122023025072A2 (pt) Usos de compostos bifuncionais para degradar btk por meio da via da ubiquitina-proteossoma
HK1238642A1 (en) Carbazole derivatives
HK1238642B (en) Carbazole derivatives

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000